Bayer: 5 new Phase III drugs expected in 2015

Share this article:

Bayer said Tuesday that it is accelerating its pipeline and expects to have five drugs in Phase III testing in 2015. The drug maker said in a statement that the drugs will swell its oncology, cardiology and women's health list of experimental treatments.

This is in addition to working on expanding the list of indications for drugs including heart drug Xarelto, cancer medication Xofigo and eye treatment Eylea.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.